Immuron Ltd — Investor Presentation 2019

Nov 3, 2019

==> picture [197 x 48] intentionally omitted <==

==> picture [347 x 345] intentionally omitted <==

FORGING COMMERCIAL & CLINICAL PATHWAYS

TARGETING INFECTIOUS DISEASES WITH ORAL IMMUNOTHERAPIES – NOVEMBER, 2019

GARY S. JACOB, Ph.D. CEO

NASDAQ: IMRN ASX: IMC

1

SAFE HARBOR STATEMENT

==> picture [55 x 53] intentionally omitted <==

Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements.

Immuron believes the statements are based on reasonable are Although forward-looking assumptions, they subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

==> picture [143 x 35] intentionally omitted <==

COMPANY HIGHLIGHTS

==> picture [55 x 53] intentionally omitted <==

• We are a commercial and clinical stage biopharmaceutical company focusing on infectious diseases with oral immunoglobulin-based therapies

• Validated Technology Platform – with One Registered Asset, Travelan® Generating Revenue

• IMM-124E & IMM-529, in Clinical Development for Treatment of Gastrointestinal Disorders and C. difficile Infections

• Plan for Accelerated R egulatory Path to Approval for IMM-124E (Travelan®) as Drug to Prevent Travelers’ Diarrhea in USA

==> picture [143 x 35] intentionally omitted <==

DEVELOPMENT PIPELINE: THREE-PRONGED PLAN

==> picture [55 x 53] intentionally omitted <==

DEVELOPMENT STAGE HIGHLIGHTS PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET ANTI-INFLAMMATORY PROGRAMS TGA ARTG Aust L106709 (2004) Commercial product - Australia Health Canada NPN 80046016 (2015) Travelan® Commercial product - Canada Dietary supplement (2015) Commercial product - USA PLAN TO DEVELOP AS DRUG TO 1 IMM-124E (Travelan®) PREVENT TRAVELERS’ DIARRHEA IN USA TO PREVENT RECURRENCE IN 2 IMM-529 C. DIFFICILE PATIENTS US ARMY – SHIGELLA Department of Defense 3 US NAY - CAMPLYLOBACTER Program

==> picture [143 x 35] intentionally omitted <==

PLATFORM OVERVIEW: ORAL IMMUNOGLOBULINS

==> picture [55 x 53] intentionally omitted <==

==> picture [812 x 280] intentionally omitted <==

----- Start of picture text -----

Toxin
Neutralization
+
Oral
Isolation of
Development Antimicrobial Clearance of
hyperimmune
of Highly
therapeutics targeted gut
antibody-rich
Specific without pathogens
bovine
Vaccines
drawbacks of
colostrum
antibiotics
----- End of picture text -----

==> picture [143 x 35] intentionally omitted <==

MECHANISM OF ACTION -TARGETING ENTERIC PATHOGENS

==> picture [55 x 53] intentionally omitted <==

==> picture [116 x 176] intentionally omitted <==

----- Start of picture text -----

Pre-Clinical
Studies
----- End of picture text -----

• Delivers high levels of orally active antibodies to specific enteric pathogenic bacteria which colonize the gastrointestinal tract and cause infection and disease.

• Biological therapeutics which directly target the major pathogenic virulent components;

• Molecules which facilitate bacterial adhesion to host cell intestinal epithelium

• Surface layer proteins which contribute to bacterial colonization and motility

• Endotoxins and enterotoxins that cause disease

With Travelan[®] : Bacteria neutralized by Travelan antibodies

Without Travelan[®] : Bacteria attach to gut wall and infect

==> picture [308 x 161] intentionally omitted <==

==> picture [288 x 159] intentionally omitted <==

==> picture [143 x 35] intentionally omitted <==

US DOD R&D COLLABORATION AGREEMENTS

==> picture [55 x 53] intentionally omitted <==

• Collaboration on Development: 1) Shigella-Specific Target – US Army 2) Campylobacter-specific Target – US Navy

• Armed Forces Research Institute of Medical Sciences (AFRIMS) – June 2016

• Naval Medical Research Center (NMRC) – August 2016

• Walter Reed Army Institute of Research (WRAIR) – June 2016

• Travelan® binds 180 pathogenic strains of bacteria from infected personnel deployed in Bhutan, Cambodia, Nepal and Thailand

==> picture [130 x 120] intentionally omitted <==

==> picture [112 x 113] intentionally omitted <==

==> picture [249 x 113] intentionally omitted <==

==> picture [55 x 53] intentionally omitted <==

New U.S. Department of Defense Research Collaboration with Immuron to Develop and Clinically evaluate a New Therapeutic against Campylobacter

Key Highlights:

• AU $5.5 (USD $3.7) million funding approved by the U.S. Department of Defense to develop and clinically evaluate a new oral therapeutic targeting Campylobacter and ETEC

• Naval Medical Research Center will fund the manufacture and therapeutic evaluation of the new therapeutic to protect against acute infectious diarrhea

• Two human clinical trials to be conducted with new therapeutic under terms of grant

Melbourne, Australia, October 02, 2019: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the funding of a new research agreement with the Naval Medical Research Center (NMRC), Silver Spring, MD, USA.

==> picture [143 x 35] intentionally omitted <==

BACKGROUND OF TRAVELAN®: PLAN TO EXPAND USE

==> picture [55 x 53] intentionally omitted <==

COMMERCIAL PRODUCT

DRUG CANDIDATE IMM-124E

Marketed in Australia, USA and Canada

==> picture [132 x 105] intentionally omitted <==

==> picture [84 x 44] intentionally omitted <==

Plan to develop IMM-124E as an approved drug to prevent Travelers’ Diarrhea

Status with FDA: IND 14,933*

==> picture [67 x 68] intentionally omitted <==

*IMM-124E for treatment of NASH

==> picture [143 x 35] intentionally omitted <==

WHAT IS TRAVELERS’ DIARRHEA?

==> picture [382 x 385] intentionally omitted <==

• Caused by consuming food or water infected with pathogens. Three or more unformed stools in 24 hours.

• .

• Bacterial pathogens are the predominant risk[1]

• Enterotoxigenic E. coli (ETEC) are the :

• predominant pathogens[2,3]

42% in Latin America

28% in Southeast Asia

• Up to 70% of travelers suffer from travelers’ diarrhea[4] .

• 1 – Steffen, R. 2017 Epidemiology of travelers’ diarrhea. Journal of Travel Medicine 24(1)

• 2 – Leder, K. 2015 Advising Travellers about Management of Travelers’ Diarrhea. Australian Family Physician, vol 44 No. 1-2 Jan. Feb 2015

==> picture [55 x 53] intentionally omitted <==

• 3 – Castelli et. al., Epidemiology of Travelers’ Diarrhea, J. Travel Medicine 2001; 8 (Suppl2) S26-S30

• 4 – CDC Yellow Book 2018, Chapter 2 Travelers’ Diarrhea.

==> picture [143 x 35] intentionally omitted <==

ANTIBIOTIC RESISTANCE: OPPORTUNITY FOR TRAVELAN®

==> picture [55 x 53] intentionally omitted <==

==> picture [214 x 45] intentionally omitted <==

: International Society of Travel Medicine, 2017 guidelines for treating Travelers’ Diarrhea included[1]

• Antibiotics should NOT be used routinely, except patients at high risk of complications

• Rifaximin recommended when antibiotic prophylaxis is indicated

• Fluoroquinolones not recommended for prophylaxis[2]

• Insufficient evidence to recommend prebiotics or probiotics

The opportunity: Travelan®, the alternative to antibiotic treatment of TD

• 1 Riddle et al. 2017. Guidelines for the prevention and treatment of travellers’ diarrhea: a graded expert panel report. Journal of Travel Medicine 24(1).

==> picture [143 x 35] intentionally omitted <==

• 2 Tribble, D. 2017 Resistant pathogens as causes of traveller’s diarrhea globally and impact(s) on treatment failure and recommendations. Journal of Travel Medicine 24(1)

TRAVELAN® AS A DRUG TO PREVENT TRAVELERS’ DIARRHEA

==> picture [55 x 53] intentionally omitted <==

• Travelan® evaluated in two randomised, double-blind, placeboControlled Human Infection Model challenge clinical trials

Oral challenge with O78 ETEC strain (H10407)

==> picture [212 x 203] intentionally omitted <==

----- Start of picture text -----

PLACEBO IMM-124E
400mg TID
15 15
----- End of picture text -----

Diarrhea was defined as passage of two or more unformed stools during 48 hour period within 72 hours of the challenge

• 90 healthy volunteers in Study 1 & 2

• Published in Scandinavian Journal of Gastroenterology

==> picture [146 x 178] intentionally omitted <==

Otto et al. 2011 Randomized Control Trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by ETEC in volunteers. Scandinavian Journal of Gastroenterology, 2011; 46: 862–868.

==> picture [143 x 35] intentionally omitted <==

SUMMARY OF RESULTS FROM STUDY 1

==> picture [55 x 53] intentionally omitted <==

Treatment Group

Treatment Group	Treatment Group	Treatment Group	Treatment Group
Placebo Colostrum_p_
Number of volunteers	15	15
Number of volunteers with diarrhea	11 (73%)	1 (7%)	0.0005
Number of diarrheal stools/volunteer (mean + SEM)	4.4±0.9	0.4±0.4	0.0004
Mean number of diarrheal stools per volunteer with diarrhea (mean and range)	6 (2 – 8)	6 (6)	NS
Abdominal pain	5 (33%)	0 (0%)	0.04
ETEC H10407 isolated from feces after challenge	15 (100%)	12 (80%)	NS

*Fisher’s exact test or Student’s t-test (two-tailed) as appropriate. NS, not significant

==> picture [143 x 35] intentionally omitted <==

TRAVELAN®: ORAL CHALLENGE STUDY PREVENTION OF SHIGELLOSIS (BACILLARY DYSENTERY) IN PRIMATES*

==> picture [55 x 53] intentionally omitted <==

• 12 juvenile rhesus monkeys randomly assigned to Travelan® (n=8) or placebo (high protein milk powder) (n=4) treatment groups

• Travelan® or placebo (500mg) was administered 2x daily for 6-days, starting on day 0

• Each monkey challenged with 2.8 x 10[9] Shigella flexneri 2a intragastrically on day 3

• Travelan® /placebo treatment stopped on day-6. Monkeys monitored through to day 14

• Faecal samples taken 2 x daily and cultured to establish presence/absence of Shigella flexneri

• Animals continually monitored for clinical signs

• *Collaborative animal model study with AFRIMS & WRAIR

==> picture [165 x 166] intentionally omitted <==

==> picture [143 x 35] intentionally omitted <==

==> picture [55 x 53] intentionally omitted <==

RESULTS OF TRAVELAN® SHIGELLA CHALLENGE STUDY*

==> picture [669 x 363] intentionally omitted <==

----- Start of picture text -----

3 x10 [9]
S. flexneri
“Travelan®” x 6 days No Treatment x 8 days
DAYS 1 2 3 4 5 6 7 8 9 10 11 12 13 14
“Placebo” x 6 days
1
----- End of picture text -----

S. flexneri was undetectable in consecutive fecal samples by day 7 in 4 of 6 (67%) survivors and by day 9 in the remaining 2 (33%) survivors

= last day of S. flexneri consecutive +ve stool culture

*Collaboration with AFRIMS & WRAIR

==> picture [143 x 35] intentionally omitted <==

IMM-124E DRUG DEVELOPMENT PLAN

==> picture [55 x 53] intentionally omitted <==

Revamp Travelan® for FDA approval as drug to prevent Travelers’ Diarrhea (TD) in travelers to endemic areas:

==> picture [804 x 214] intentionally omitted <==

----- Start of picture text -----

  File IND with
Plan for Double- Execute
Assimilate Data Hold Pre-IND
Blind, Placebo Prevention Trial
to Support IND Meeting to Controlled Trial and File
Submission to Discuss Merits of
for Prevention of Registration
FDA to Prevent Application to Travelers’ Package
TD Prevent TD
Diarrhea
----- End of picture text -----

==> picture [143 x 35] intentionally omitted <==

TRAVELAN® COMMERCIAL PROFILE: INCREASING SALES ADDRESSING LARGE MARKETS

==> picture [55 x 53] intentionally omitted <==

==> picture [162 x 11] intentionally omitted <==

----- Start of picture text -----

Global Immuron Sales - AUD
----- End of picture text -----

2019 Global market - US $630M Expected to reach US $890M by 2024 at 7% CAGR[1]

==> picture [416 x 232] intentionally omitted <==

----- Start of picture text -----

$2.6M
$3,000,000
$2,500,000 $2.01M
$2,000,000
$1.38M
$1,500,000
$1,000,000
$500,000
$-
FY17A FY18A FY19A
----- End of picture text -----

1. https://www.marketwatch.com/press-release/at-71-cagrtravelers-diarrhea-therapeutics-market-size-to-reach-usd890-million-by-2024-2019-05-08

==> picture [31 x 12] intentionally omitted <==

----- Start of picture text -----

AUD
----- End of picture text -----

==> picture [143 x 35] intentionally omitted <==

Immuron North American revenue surges by 52% in FY19

==> picture [55 x 53] intentionally omitted <==

Key Highlights:

• Immuron FY19 revenue surged by 52% in North America, reaching $1.16M.

• In the USA, FY19 Travelan® sales exceeded the $1M AUD milestone for the first time and grew by +32% to $1.02M AUD.

• In May 2019, USA Travelan® sales achieved a record-breaking $182K AUD.

• The first Canadian sales of Travelan® were reported in Q4 of FY19.

• Global Immuron sales for FY19 grew at +29% YoY, representing a recordbreaking year for the company with revenue before rebates reaching $2.6M AUD.

Melbourne, Australia, July 16, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, today announced sales results for the year ended 30 June 2019 (‘FY19’) for its commercially available products, including Travelan®, the over-the-counter gastrointestinal and digestive health supplement.

==> picture [143 x 35] intentionally omitted <==

==> picture [55 x 53] intentionally omitted <==

Immuron North American Q1 Sales Up 111% YoY

Key Highlights:

• First Quarter of FY2020 (Q1) North American sales grew by 111% YoY to $269K AUD

• Q1 US Travelan® sales increased by +81% YoY to $232K AUD

• Global Immuron sales continued an upward trend in Q1 with a +54% YoY sales increase, reaching $741K AUD

• In Australia, Q1 Travelan® sales increased by +34% YoY to $458K AUD

Melbourne, Australia, October 14, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut-mediated pathogens, is pleased to announce sales results for its commercially available, over-the-counter gastrointestinal and digestive health supplement Travelan®, for the quarter ended September 30, 2019, of fiscal year 2020 (Q1).

==> picture [143 x 35] intentionally omitted <==

GLOBAL TRAVELAN® SALES (AUD)

==> picture [55 x 53] intentionally omitted <==

Global Immuron Sales - AUD

==> picture [829 x 292] intentionally omitted <==

----- Start of picture text -----

• FY19 YoY revenue [1] growth: 23%
• Q1 FY20 YoY revenue [1] growth: 54%
$2.6M
$3,000,000
$2,500,000 $2.01M
$2,000,000
$1.38M
Sales by region
$1,500,000
CANADA
6%
$1,000,000 USA
40%
$500,000 AU
54%
$-
FY17A FY18A FY19A
----- End of picture text -----

==> picture [106 x 178] intentionally omitted <==

----- Start of picture text -----

Sales by region
CANADA
6%
USA AU CANADA
----- End of picture text -----

1 - Revenue before rebates.

FY20 MARKETING OVERVIEW: USA

FY19 REVIEW

• USA website launched June 2019.

• Increased sales in 190 Passport Health Clinics across the USA.

• Travel blogger & influencer collaborations to target travellers (28 globally).

• Training & incentive program for travel clinic nurses.

• 2 podcast campaigns to stimulate Amazon sales (80% uplift in YoY Medique sales).

FY20 APPROACH

• Integrated consumer awareness campaign planned for Feb 2019 (influencer, travel advertorial & earned media components).

• • Amazon cross-promotions with travel influencers - starting Nov 19.

• Expansion into additional 35+ Passport Health travel clinics.

• Continued training programme for travel nurses.

• Podcast interview with Passport Health Travel Nurse for consumer targeted advertising.

• Amazon paid promotions.

• 4 podcast interviews to stimulate Amazon sales.

==> picture [235 x 259] intentionally omitted <==

==> picture [247 x 190] intentionally omitted <==

----- Start of picture text -----

21
----- End of picture text -----

US SALES FORECAST FOR TRAVELAN®: IF APPROVED AS DRUG TO PREVENT TD

==> picture [55 x 53] intentionally omitted <==

MARKET POTENTIAL FOR TRAVELAN® SALES:

Market potential figure derived from:

2014 figures of US citizens traveling to high risk destinations for TD (44.3 million)[1] and obtaining pretravel advice (22.2 million)[2] . Sources of pre-travel advice include primary care provider, travel medicine specialist, company doctors, pharmacist, and travel agencies[2] . Our forecast utilizes a very conservative estimate for % of US citizens purchasing Travelan® after seeking pre-travel advice.

==> picture [342 x 188] intentionally omitted <==

1. U.S. Department of Commerce, International Trade Administration, National Travel and Tourism Office. U.S. Citizen Traffic to Overseas Regions, Canada & Mexico 2014. Monthly Statistics, U.S.Outbound Travel by World Regions. 2014. Available at: http://travel.trade.gov/view/m-2014-O-001/index.html. Accessed June 26, 2015.

2. Mathyas Wang , MD , Thomas D. Szucs , MD, MBA, MPH, LLM , and Robert Steffen , MD. Economic Aspects of Travelers ’ Diarrhea. Journal of Travel Medicine, Volume 15, Issue 2, 2008, 110–118

==> picture [143 x 35] intentionally omitted <==

==> picture [55 x 53] intentionally omitted <==

COMPETITOR MARKET ANALYSIS – ANTI-DIARRHEAL DRUGS

Drug	Indication	Dosing	Ave cost – 2 week trip	Revenue USD Millions (Year)
FDA APPROVED DRUG TREATMENTS FOR DIARRHEA
PEPTO BISMOL (BSS)	Relief for heartburn, nausea, indigestion, upset stomach and diarrhea.	2 tabs QID	$20.971	82.6 (2013)2
IMMODIUM	Decrease the frequency of diarrhea in TD, gastroenteritis, inflammatory bowel disease, and short bowel syndrome.	2 tabs (2 mg)	$17.331 (48 caplets)	82.5 (2013)2
CIPROFLOXACIN (FLUOROQUINOLINE)	Bacterial infections.	500 mg	$44.523	40.8 (2015)3
RIFAXIMIN	Treatment of Travellers’ Diarrhea.	3 caps (200 mg) TID	$6574
PRESENTLY, THERE IS NO FDA APPROVED DRUG TO PREVENT TRAVELERS’ DIARRHEA
TRAVELAN®	Dietary Supplement.	3 caps (200 mg) TID	$30 – 30 caplets	0.77 (2018)5

1. Amazon.com

2. Top 10 OTC brands for digestives by revenue in the USA in 2013

3. Almalki et. al., Utilization, spending & price trends for quinolones in the US, Pharmacoecon Open 2017 Jun: 1(2): 123-131

4. Drugs.com Xifaxan (rifaximin) price guide. Cost of Xifaxan oral tablet 200 mg ~$657 for 30 tablets

==> picture [143 x 35] intentionally omitted <==

1. US Sales for Travelan – FY2018

==> picture [55 x 53] intentionally omitted <==

NEUTRALIZING CLOSTRIDIUM DIFFICILE , WHILE SPARING THE MICROBIOME

IMM-529

==> picture [386 x 386] intentionally omitted <==

==> picture [143 x 35] intentionally omitted <==

CLOSTRIDIUM DIFFICILE MARKET OPPORTUNITY

==> picture [55 x 53] intentionally omitted <==

Clostridium difficile ( C. difficile ) is a bacterium that causes diarrhea and more serious intestinal conditions such as colitis

• Therapeutic market expected to grow from USD $630 million in 2016 to over $1.7 billion by 2026 – CAGR 15%[1]

• Leading cause of gastroenteritis-associated mortality in U.S.[2]

• Approx. 44,500 patients[3] died in 2014 from C. difficile infections (U.S.)

• • Potential orphan disease (7 years market exclusivity and premium pricing)

• https//www.globaldata.com/global-clostridium-difficle-infectionmarket-approach-2016-2026

• Jagai, et.al., BMC Gastroenterology, 2014:14:211 Trends in gastroenteritis-associated mortality in the USA.

• K. Desai, BMC Infect. Dis., 2016,16:303

==> picture [143 x 35] intentionally omitted <==

THE UNMET NEED

==> picture [55 x 53] intentionally omitted <==

• Current standard of care for C. difficile includes vancomycin, metronidazole & fidaxomicin

• Therapies plagued by significant CDI recurrences ( 1st relapse: 25%; 2nd: 40%; 3rd: 60%) underscoring need for new treatments

• Growing resistance to vancomycin treatment

• Some treatments are administered intravenously rather than via the gut where C. difficile resides

==> picture [237 x 158] intentionally omitted <==

==> picture [143 x 35] intentionally omitted <==

• *Isobel Ramsay, Nicholas Brown and David Enoch. Recent Progress for the Effective Prevention and Treatment of Recurrent Clostridium difficile Infection. Infectious Diseases: Research and Treatment Volume 11: 1–4 (2018). DOI: 10.1177/1178633718758023

IMM-529 OPPORTUNITY

• IMM-529 highly differentiated – neutralizes C. difficile but does not impact microbiome

• Targets not only toxin B but also spores and vegetative cells responsible for recurrence

• Potential use in combination with standard of care

• Targets many isolates

==> picture [55 x 53] intentionally omitted <==

==> picture [249 x 242] intentionally omitted <==

==> picture [143 x 35] intentionally omitted <==

THE C. DIFFICILE PREVENTION OF RECURRENT CDI MOUSE MODEL*

==> picture [55 x 53] intentionally omitted <==

C57BL/6mice 6–7 weeks

==> picture [397 x 156] intentionally omitted <==

----- Start of picture text -----

C. difficile challenge
(10 [3] spores)
Day -10 -1 0
----- End of picture text -----

Administration of water or IMM-529 +8 Vancomycin treatment ceases

Antibiotics in drinkingwater to induce susceptibility to C. difficile

Monitor:

• Weight loss

• Physiological appearance

Administration of vancomycin alone or vancomycin + IMM-529 12 hour post infection

• Activity

• Diarrhoea

==> picture [143 x 35] intentionally omitted <==

*Collaboration with Prof. Dena Lyras, Monash University, Australia

IMM-529 ANIMAL MODEL ‘RECURRENCE’ STUDY

==> picture [55 x 53] intentionally omitted <==

Relapse Study

==> picture [643 x 280] intentionally omitted <==

----- Start of picture text -----

S u rv iv a l
1 1 0
In fe c te d + S O C
1 0 0
9 0 ** In fe c te d + S O C + IM M -5 2 9
8 0 p=0.0027
7 0
6 0
5 0
4 0
3 0
2 0
1 0
0
0 2 4 6 8 1 0 1 2 1 4 1 6 1 8 2 0
D a y s a fte r v a n c o m y c in tre a tm e n t c e a s e d
P e rc e n t s u rv iv a l
----- End of picture text -----

==> picture [176 x 101] intentionally omitted <==

----- Start of picture text -----

All studies
statistically
significant
----- End of picture text -----

Demonstrated ~80% survival rate (7/9) vs. ~10% survival rate in control group (1/9)

==> picture [143 x 35] intentionally omitted <==

THE C. DIFFICILE PREVENTION MOUSE MODEL

C57BL/6mice 6–7 weeks

Vancomycin or IMM-529administration

==> picture [201 x 130] intentionally omitted <==

==> picture [681 x 120] intentionally omitted <==

----- Start of picture text -----

Day -10 -3 -2 -1 0
Antibiotics in drinkingwater to C. difficile challenge
induce susceptibility to C. difficile (10 [3] spores)
----- End of picture text -----

Monitor:

Antibiotics in drinkingwater to induce susceptibility to C. difficile

• Weight loss

==> picture [55 x 53] intentionally omitted <==

• Physiological appearance

• Activity

• Diarrhoea

==> picture [143 x 35] intentionally omitted <==

*Collaboration with Prof. Dena Lyras, Monash University, Australia

IMM-529 ANIMAL MODEL STUDY

==> picture [115 x 79] intentionally omitted <==

----- Start of picture text -----

All studies
statistically
significant
----- End of picture text -----

==> picture [813 x 377] intentionally omitted <==

----- Start of picture text -----

Prevention Study statistically
significant
S u rv iv a l
1 0 0
U n in fe c te d , N o tre a tm e n t
8 0 In fe c te d , N o tre a tm e n t
In fe c te d , N o n -im m u n e Ig G tre a tm e n t
6 0 In fe c te d , IM M -5 2 9 tre a tm e n t
In fe c te d , V a n c o m y c in tre a tm e n t
4 0
2 0
Demonstrated
00 .0 0 .5 1 .0 1 .5 2 .0 2 .5 3 .0 3 .5 4 .0 80% efficacy
h o u rs p o s t in fe c tio n without use of
antibiotics
P e rc e n t s u rv iv a l
----- End of picture text -----

==> picture [55 x 53] intentionally omitted <==

==> picture [143 x 35] intentionally omitted <==

IMM-529 DRUG DEVELOPMENT PLAN

==> picture [55 x 53] intentionally omitted <==

Develop clinical protocol for FDA approval as drug to prevent recurrent Clostridium difficile Infection:

==> picture [807 x 215] intentionally omitted <==

----- Start of picture text -----

File IND with
Hold pre-IND
Develop clinical plan for placebo
meeting to Execute
registration controlled trial
discuss clinical recurrence
strategy for FDA for prevention of
protocol and prevention trial
submission disease
strategy
recurrence
----- End of picture text -----

==> picture [143 x 35] intentionally omitted <==

COMPETITOR MARKET ANALYSIS – CDI

==> picture [55 x 53] intentionally omitted <==

Company		Drug	Type	Status
Reduce recurrence of CDI
Zinplava (bezlotoxumab) IV Monoclonal Antibody FDA approved 2016
SER-109 Oral microbiome therapeutic Phase 3
CP101 Oral microbiome therapeutic Phase 2
Treatment of Primary CDI
Ridinilazole Oral antibiotic Phase 3
Cadazolid Oral antibiotic Failed Phase 3
SER-262 Oral microbiome therapeutic Phase 1b

==> picture [143 x 35] intentionally omitted <==

*As of March 25, 2019

KEY MILESTONES EXPECTED TO DRIVE VALUE

==> picture [55 x 53] intentionally omitted <==

2H 1H 2H 2021 2019 2020 2020 • Pre-IND Meeting to • Initiate Phase 3 • Phase 3 IMM• Plan to File BLA Discuss IMM-124E Clinical Trial on 124E TD for IMM-124E Phase 3 Clinical IMM-124E TD Clinical Data TD prevention Development prevention study Available study • • Pre-IND Meeting Plan to initiate  on IMM-529 C. U.S. Phase 2 Results from US Army Shigella animal difficile program trial on IMMstudies expected in 2020 529 to treat In vitro r esults from US Navy NMRC recurrent CDI studies expected 2020

==> picture [143 x 35] intentionally omitted <==

MANAGEMENT

==> picture [55 x 53] intentionally omitted <==

==> picture [130 x 135] intentionally omitted <==

==> picture [141 x 56] intentionally omitted <==

• Chief Executive Officer of Immuron Limited since November 16, 2018.

• Over 30 years of experience in pharmaceutical and biotechnology - including R&D, operations, business development and capital financing.

• Co-founder and founding CEO of Synergy Pharmaceuticals.

• Co-inventor of TRULANCE® (plecanatide), an FDA approved drug to treat chronic GI disorders.

• Raised over USD $500 million of capital in the public markets to support Synergy from founding to approval of TRULANCE® in 2017.

• Ph.D. in Biochemistry; University of Wisconsin-Madison and BS in Chemistry from the University of Missouri.

==> picture [141 x 141] intentionally omitted <==

==> picture [154 x 55] intentionally omitted <==

• Former Acting CEO of Immuron Ltd. Over twenty years’ experience in pharmaceutical and biotechnology industries.

• Former Chief Operating Officer of TransBio Ltd. Responsible for strategic identification, development and maintenance of global commercial partnerships, along with development, management and IP portfolio, R&D and technology transfer.

• Leadership roles in business development, project management, IP portfolio management, R&D, senior management.

• Consultant to academic institutes, private and publicly listed companies and government departments specializing in development and commercialization strategies.

• PhD in medicine from the University of Melbourne.

BOARD OF DIRECTORS – CHAIRMAN & EXECUTIVE VICE CHAIRMAN

==> picture [55 x 53] intentionally omitted <==

==> picture [133 x 134] intentionally omitted <==

Dr Roger Aston

CHAIRMAN - B. Sc. (Hons), PhD.

Dr Aston has more than 20 years experience in the pharmaceutical and biotech industries. He was Chief Executive Officer of Mayne Pharma Group Limited, after leading HalcyGen’s acquisition of Mayne Limited in 2009. He has extensive experience with FDA and EU product registration, clinical trials, global licensing, private placement fundraising and prospectus preparation. Dr Aston has held numerous other board positions in the sector including with Clinuvel Limited, HalyGen Limited and Ascent Pharma Health Limited, recently acquired by Watson.

==> picture [133 x 130] intentionally omitted <==

Peter Anastasiou

EXECUTIVE VICE CHAIRMAN - BBSc

Mr. Anastasiou has extensive business experience in a wide range of organisations. He has been a successful entrepreneur from and early age with his first biotech venture, Neuro Developments Australia, seeded at age 24. Mr. Anastasiou was the founder of Investment Group Grandlodge, and ACS International both of which have generated significant wealth through Investment and Management.

NON-EXECUTIVE DIRECTORS

• Dr Gary Jacob

• Stephen Anastasiou

• Daniel Pollock

• Professor Ravi Savarirayan

==> picture [143 x 35] intentionally omitted <==